Le Lézard
Classified in: Health, Science and technology, Business
Subject: JVN

Ovensa Collaborates with Takeda to Deliver an Antibody to the Brain


AURORA, ON, March 21, 2019 /CNW Telbec/ - Ovensa Inc. ("Ovensa") is pleased to announce that it has entered into a collaboration agreement with Takeda Pharmaceutical Company Limited ("Takeda") to evaluate Ovensa's proprietary nanomedicine platform called TRIOZANtm for the delivery of an antibody to the brain and evaluate its performance in a CNS disease model.

"We are extremely proud of this new partnership, which demonstrates a great deal of confidence in our unique delivery system which helps therapeutic molecules better cross the human body's various barriers such as the skin, the mucous membranes or the blood-brain barrier and reach their target. Takeda is the largest pharmaceutical company in Japan and is present in more than 70 countries. We are starting this collaboration with enthusiasm and hope that this partnership will accelerate the discussions we have with some 30 other companies, "says Ovensa's President and CEO, Mr. Stéphane Gagné.

Ovensa offers a platform allowing for the development of custom nanomedicines based on trimethylchitosan - a biopolymer derived from crustacean chitosan. Whether it is for reducing the side effects of chemotherapy, changing the expression of a gene that does not function normally or eliciting an optimal immune response of an antibody in the brain, the platform allows high engineering flexibility where nanomedicines are specifically designed to cross barriers and optimize tissue or cell targeting based on the disease.

Although Ovensa's platform research focuses on complex diseases for which there are few available treatments such as brain cancer and Alzheimer's Disease, it also applies to other therapeutic areas such as metabolic diseases, animal health or antibiotic resistance. Also using its patented TRIOZANtm platform, Ovensa is conducting trials with its collaborators to develop new custom nanomedicines using cannabinoids such as cannabidiol (CBD) to treat various diseases including certain cancers, diseases of the central nervous system and pain.

Terms of the agreement with Takeda have not been disclosed.

About Ovensa

Ovensa is a preclinical stage company fighting inherent therapeutic resistance in complex diseases by generating advanced nanotherapeutics using its proprietary TRIOZANtm Delivery Platform. The company focuses on advancing its lead candidate in glioblastoma as well as generating novel nanotherapeutic candidates in collaboration with pharmaceutical companies for applications in CNS and immuno-oncology.

 

SOURCE Ovensa


These press releases may also interest you

at 21:05
Logitech International (SIX: LOGN) today announced financial results for the first quarter of Fiscal Year 2020. Q1 sales were $644 million, up 6 percent in US dollars and 9 percent in constant currency, compared to Q1 of the prior year. Q1 GAAP...

at 21:00
Vymo (www.getvymo.com), a New York-based next-generation CRM startup, that uses mobility and intelligence as key levers to improve field force productivity, was commended at Innovfest Unbound 2019 by ONE (Ocean Network Express), one of the world's...

at 20:20
The number of people working remotely has been growing steadily for the last decade. It's estimated that remote workers now make up around 50% of the total US workforce, and, according to a recent study by IWG, as much as 70% of the global workforce...

at 20:17
Member of Parliament for Northwest Territories, Michael McLeod, on behalf of Canada's Minister of Natural Resources, the Honourable Amarjeet Sohi, will announce clean energy investments for Canada's North. A media availability will follow.   Date:...

at 20:06
Systems Planning and Analysis, Inc. (SPA) has acquired Veracity Forecasting and Analysis, Inc. (Veracity).  Terms of the transaction, which closed on July 21, are not being disclosed. Veracity provides decision support...

at 20:00
ThetaRay, a leading provider of AI-based Big Data analytics, today announced Version 4.0 of the company's namesake advanced analytics platform. The update includes major capability upgrades to help global banks detect and prevent financial...



News published on 21 march 2019 at 07:00 and distributed by: